During yesterday’ session, “WFH Humanitarian Aid Program: Past and future” the many achievements and the future objectives of the WFH Humanitarian Aid Program were presented to the participants of the WFH Virtual Summit. Assad E. Haffar, MD, WFH Medical & Humanitarian Aid Director, went over the many accomplishments that have been realized by the Program over the last five years.
Megan Adediran and Kibet Shikuku went over how the Program can help countries implement a sustainable hemophilia care program. And Glenn Pierce, MD, PhD, WFH Vice-President, Medical, went over how gene therapy is potentially the next piece of the puzzle for a sustainable future for those with a bleeding disorder. Alain Baumann, WFH CEO, warmly introduced the speakers who represented the donors of the WFH Humanitarian Aid Program.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer, our Visionary Contributor; Grifols and Roche, our Leadership Contributors; and our Contributor, CSL Behring. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org